Tenosynovial giant cell tumor (TGCT) is a group of rare tumors. They are usually benign (not cancer) and tend to occur in people between 25 to 50 years old. The tumors affect areas of the joints ...

Results from a phase 1 trial showed the independently reviewed best overall objective response rate was 71% in emactuzumab-treated patients. The Food and Drug Administration (FDA) has granted Fast ...

A committee consisting of Dr. Codman, Dr. Ewing and Dr. Bloodgood studied a large number of cases of bone tumors, and from them they separated a group of benign giant-cell tumors. Up to that time ...

Romvimza is a medicine called a kinase inhibitor that is used to treat tenosynovial giant cell tumor (TGCT) that may be made worse by surgery. TGCT is a condition where tumors form in joints of ...

Emactuzumab demonstrated a 71% objective response rate, rapid tumor reduction, and manageable side effects in early trials. Emactuzumab has received fast track designation from the U.S. FDA for ...

a drug that Abbisko Therapeutics has advanced to late-stage clinical development for tenosynovial giant cell tumor, a type of tumor that forms in and around joints. Besides surgery, the only FDA ...

The U.S. Food and Drug Administration (FDA) has approved vimseltinib (Romvimza) for adult patients with a rare condition ...